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Needs 
• Transplantation is an effective and well-
established treatment that can significantly 
benefit citizens facing illness, disability or 
premature death.  
• Demand for organs for transplantation continues 
to exceed supply  
• Despite the improvements in donation and 
transplantation outcomes, countries have not 
met the increasing demand for organs 
transplantation.  
 
 
General goals 
• To optimise every donation opportunity (multiorgans, 
tissues and cells)  
• To maximise donation rates, increasing the capability 
and capacity within the health system  
• To promote organ and tissue donation, building 
community awareness and stakeholder engagement 
• To implement safe, ethical and effective organ and 
tissue donation and transplantation systems 
• To promote international cooperation to share best 
practice  
• To promote financial sustainability  
Exemplo de estrutura (Barcelona) 
AMERICAN ASSOCIATION OF TISSUE BANKS 
STANDARDS FOR TISSUE BANKING -1 
• A1.000 ACCREDITATION 
 
• A2.000 DEFINITIONS OF TERMS 
 
• B1.000 GENERAL INSTITUTIONAL 
REQUIREMENTS 
– B1.100 Purpose, Institutional Identity, and 
Affiliations 
– B1.200 Governing Body 
– B1.300 Medical/Scientific Support 
– B1.400 Satellite Facilities 
– B1.500 Multi-Facility Tissue Banking 
• B1.510 Written Agreements/Contracts 
• B1.520 On-Site Inspections 
– B1.521 Inspections/Audits of Other 
Facilities 
– B1.600 Contracted and Non-contracted 
Laboratory Services 
 
• B2.000 FUNCTIONAL COMPONENTS OF A TISSUE 
BANK 
B2.100 Management Responsibility 
– B2.110 Quality Policy 
– B2.120 Organization 
• B2.121 Responsibilities and Authority 
• B2.122 Resources 
• B2.123 Management Representative 
– B2.130 Management Review 
– B2.140 Technical Policies and Procedures 
– B2.150 Quality Assurance Program 
 
B2.200 Medical Director 
B2.210 Qualifications 
B2.220 Responsibilities 
B2.221 Donor Suitability Criteria 
B2.222 Adverse Outcomes 
B2.223 Confirmed Positive Test Results 
 
B2.300 Technical Staff 
B2.310 Qualifications 
B2.320 Responsibilities 
 
B2.400 Quality Assurance Program 
B2.410 Staff Qualifications 
B2.420 Staff Responsibilities 
 
C1.000 RECORDS MANAGEMENT 
C1.100 General 
C1.110 Required Processing Documentation 
C1.120 Electronic Records 
               C1.200 Availability for Inspection 
               C1.300 Retention 
               C1.400 Traceability 
               C1.500 Revisions 
C2.000 CONSTRUCTION OF RECORDS 
 
C3.000 DONOR RECORDS TO BE MAINTAINED 
 
C4.000 PROCESSING RECORDS TO BE MAINTAINED BY OTHERS 
 
D1.000 GENERAL POLICIES FOR TISSUE RECOVERY OR 
COLLECTION     
              ORGANIZATIONS 
               D1.100 Monetary Compensation or Other Valuable                
                            Consideration to Donors 
 
D2.000 AUTHORIZATION 
               D2.100 Requirements 
               D2.200 Conditions 
               D2.300 Signatures and Documentation 
 D2.310 Document of Gift 
 D2.320 Document of Authorization 
 D2.330 Methods of Obtaining Authorization 
                D2.400 Core Elements for Authorization 
                D2.500 Notification of Gift 
                D2.600 Services to Donor Families 
 
AMERICAN ASSOCIATION OF TISSUE 
BANKS 
STANDARDS FOR TISSUE BANKING -2 
D3.000 INFORMED CONSENT FOR LIVING 
DONORS 
               D3.100 Requirements 
               D3.200 Conditions 
               D3.300 Signatures and 
Documentation 
 D3.310 Methods of Obtaining 
Informed Consent 
               D3.400 Core Elements for Informed 
Consent 
 
AMERICAN ASSOCIATION OF TISSUE 
BANKS 
STANDARDS FOR TISSUE BANKING -3 
D4.000 DONOR SUITABILITY 
              D4.100 General 
              D4.200 Assessment 
 D4.210 Physical Assessment 
              D4.211 Physical Examination 
                           D4.220 Donor Risk Assessment 
                          4.221 (R) Family History and Genetic     
                                                  Background 
                           D4.230 Relevant Medical Records Review 
                           D4.240 Donor Autopsy Report 
 
D4.300 (A) Disease Screening 
 
              D4.310 Infections 
 
              D4.320 Miscellaneous Adverse Conditions 
 
              D4.330 Risk Factors 
 
              D4.340 Malignancies 
 
              D4.350 Blood Tests 
 D4.351 Specimens 
 D4.352 Plasma Dilution 
 D4.353 Infectious Disease Testing 
 D4.354 Required Infectious Disease Tests 
 D4.355 Interpretation of Infectious Disease Test  
                                     Results 
 D4.356 Disclosure and Availability of Positive  
                                     Infectious Disease Test Results 
 D4.357 Archived Samples 
              
D4.360 (R) Repeat Testing of Living Donors 
             D4.370 (R) Semen Analysis 
D4.400 Age Criteria 
 
D4.500 Information Sharing 
 
D5.000 RECOVERY AND COLLECTION POLICIES AND 
PROCEDURES 
             D5.100 Reagents, Supplies, Materials and  
                          Equipment 
 
             D5.110 Stock Rotation 
 
             D5.200 Donor Identification 
 
             D5.210 Verification Procedures 
 
             D5.211 Confirmation 
 
             D5.212 Donor Identity 
D5.300 Tissue Recovery and Collection — General 
            D5.310 Recovery 
            D5.320 (R) Collection 
 
D5.400 Time Limits for Tissue Recovery 
 
D5.500 Recovery Environment 
            D5.501 Recovery Site Suitability Parameters 
            D5.510 Recovery Cleansing and Preparation 
            D5.520 Recovery Technique 
            D5.521 (MS, OA, S, SB) Cultures Obtained at Recovery 
 
D5.600 Recovery Records 
 
D5.700 Post-Recovery Labeling and Handling 
 
D5.800 Transportation Following Recovery 
 
D5.900 Post-Recovery Reconstruction of a Deceased Donor 
 
E1.000 PROCESSING, PRESERVATION, QUARANTINE 
AND STORAGE—GENERAL 
          E1.010 Receipt of Tissue at Processing/Storage  
                      Facility 
 
          E1.020 Processing Environment 
 
          E1.030 Processing Methods 
               E1.031 (C, V) Documentation of Tissue Condition 
               E1.032 Temperature Limits 
               E1.033 Time Limits for Processing and  
                            Preservation Phases 
               E1.034 (C, V, S) Prevention of Matrix Deterioration 
               E1.035 (C, V, OA, R, S) Additives 
 
          E1.040 Sterilization/Disinfection of Tissue 
               E1.041 Non-Terminal Irradiation 
               E1.042 Terminal Sterilization by Irradiation 
               E1.043 Sterilization by Other Methods 
               E1.044 (MS) Disinfection by Chemical Agents 
               E1.045 (MS) Other Disinfection Agents 
 
         E1.050 Tissue Evaluation 
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E1.060 Tissue Preservation/Cryopreservation 
       E1.061 Techniques 
       E1.062 (C, V) Control-Rate Freezing: Surrogate Packages 
       E1.063 (C, V, S) Termination of Freezing Program 
       E1.064 (C, V, S) Freezing Profile 
       E1.065 (MS) Lyophilization 
       E1.066 (MS) Dehydration 
       E1.067 Freezing Tissue 
       E1.068 (OA, MS) Cryopreservation 
       E1.069 (MS) Chemical Preservation 
 
E1.100 Tissue Identification 
 
E1.200 Pooling 
       E1.210 Tissue Cross-contamination 
 
E1.300 Reagents, Supplies, Materials and Equipment 
       E1.310 Stock Rotation 
 
E1.400 Tracing of In-Process Tissue 
 
E1.500 Tolerance Limits of Processed Tissue 
       E1.510 Specimen Sizing 
       E1.520 (MS) Calcium Residuals: Demineralized Bone 
 
E1.600 In-Process Controls 
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STANDARDS FOR TISSUE BANKING -5 
E1.700 Processing and Preservation Records 
 
E1.800 In-House Laboratory Testing 
       E1.810 Laboratory Records 
       E1.820 Laboratory Controls 
 
E2.000 CONTAINERS 
       E2.100 Physical Properties 
       E2.200 Receipt of New Shipments 
       E2.300 Storage 
       E2.400 Integrity and Sterility 
       E2.500 Visual Inspection 
 
E3.000 QUARANTINING 
       E3.100 Quarantine Areas 
       E3.200 Situations Requiring Quarantine 
       E3.300 Labeling Quarantined Tissue 
       E3.400 Quarantine Records 
E4.000 STORAGE 
 
      E4.100 Storage Temperatures 
               E4.110 Refrigerated Tissue 
               E4.120 Frozen and Cryopreserved Tissue 
               E4.130 (MS) Lyophilized/Dehydrated Tissue 
               E4.140 Monitoring Storage Temperatures 
               E4.141 Storage Conditions for Commonly   
                           Transplanted Human Tissue 
               E4.150 Emergency Transfers 
 
       E4.200 Expiration Date/Storage Period 
               E4.210 Refrigerated Tissue 
               E4.220 Frozen and Cryopreserved Tissue 
               E4.230 (MS) Lyophilized/Dehydrated Tissue 
 
        E4.300 Segregation of Tissue 
 
F1.000 TISSUE RELEASE—GENERAL REVIEW 
REQUIREMENTS 
         F1.100 Donor Suitability Review 
         F1.200 Technical Review 
         F1.300 Quality Assurance/Quality Control Review 
               F1.310 Review of On-Site Processing Records 
 
F2.000 OTHER RELEASE 
         F2.100 Tissue Release Based on Tissue Utility 
         F2.200 (R) Special Circumstances in Release of  
                           Reproductive Tissues 
         F2.300 Shipping Reproductive Tissue in Quarantine 
 
F3.000 TISSUE FAILING REVIEW PROCESS—
GENERAL REQUIREMENTS 
         F3.100 Unsuitable Donors 
         F3.200 Technical or Quality Assurance 
Assessments 
 
F4.000 TISSUE RELEASE—GENERAL 
         F4.100 Release to Distribution Inventory 
         F4.200 Transfer to Other Inventory Locations 
AMERICAN ASSOCIATION OF TISSUE BANKS 
STANDARDS FOR TISSUE BANKING -6 
G1.000 LABELS AND LABELING 
      G1.100 Nomenclature 
      G1.200 Label List 
      G1.300 Labeling Integrity 
      G1.400 Claims 
 
G2.000 LABELING PROCESS 
      G2.100 General Requirements 
      G2.200 Re-Labeling 
      G2.300 Controls—General 
            G2.310 Label Inspection 
            G2.320 Label Storage 
            G2.330 Labeling Process Controls—    
                         Obsolete Labels 
            G2.340 Tissue and Container Visual Inspection 
 
G3.000 LABELING INFORMATION 
      G3.100 Container Labels 
             G3.110 Design 
             G3.120 Content 
             G3.130 Additional Labeling Requirements 
G3.200 Summary of Records and Package Insert 
      G3.210 Summary of Records Content 
      G3.220 Package Insert Content 
G3.300 Transport Package Label Content 
      G3.310 Domestic Shipments 
      G3.320 International Shipments 
 
H1.000 DISTRIBUTION AND DISPENSING—GENERAL 
                  H1.010 Solutions 
       H1.100 Tissue Distribution and Dispensing Restrictions 
                  H1.110 (R) Client Depositor Authorization 
                  H1.120 (R) Reproductive Tissue Distribution Restriction 
                  H1.130 (R) Donor Conceived Offspring Limitations 
       H1.200 Transfer of Tissue to Other Tissue  
                    Banks/DispensingServices 
       H1.300 Requests for Donor Status and Tissue Processing  
                    Information 
       H1.400 Distribution Records 
                H1.410 Responsibility 
AMERICAN ASSOCIATION OF TISSUE 
BANKS 
STANDARDS FOR TISSUE BANKING -7 
H2.000 TISSUE FOR RESEARCH—GENERAL POLICIES AND 
PROCEDURES 
       H2.100 Written Requests 
       H2.200 Review and Approval 
 
H3.000 PACKAGING AND SHIPPING 
       H3.100 Integrity 
       H3.200 Tissue Storage Environment 
       H3.300 Validation and Expiration of Transport Container 
       H3.400 Quality Control 
            H3.410 (C, V) Residual Levels in Packaging 
       H3.500 Final Inspection 
       H3.600 Transportation 
 
H4.000 RETURN OF TISSUE 
        H4.100 Temperature Records 
 
H5.000 CORRECTIONS AND REMOVALS — GENERAL 
        H5.100 Circumstances That May Require Correction or   
                     Removal 
        H5.200 Notification Responsibilities 
        H5.300 Handling of Tissue 
        H5.400 Reporting Requirements 
        H5.500 Correction and Removal Records 
AMERICAN ASSOCIATION OF TISSUE 
BANKS 
STANDARDS FOR TISSUE BANKING -8 
J1.000 STANDARD OPERATING PROCEDURES MANUAL 
(SOPM) 
      J1.100 Identification and Control 
      J1.200 Contents 
      J1.300 Implementation 
      J1.400 Modifications 
      J1.500 References 
      J1.600 Annual Review 
      J1.700 Staff Access and Review 
      J1.800 Inspections 
      J1.900 Archives 
 
J2.000 TECHNICAL AND QUALITY ASSURANCE STAFF— 
             TRAINING/CONTINUING EDUCATION 
       J2.100 Training 
       J2.200 Competency 
       J2.300 Continuing Education 
       J2.400 Training Records 
 
J3.000 SAFETY PRACTICES 
        J3.100 Work Environment 
        J3.200 Procedures 
        J3.300 Hazardous Materials Training 
        J3.400 Universal Precautions 
        J3.500 Immunization 
        J3.600 Hazardous Waste Disposal 
        J3.700 Personnel 
              J3.710 Attire 
              J3.720 Infections 
J4.000 FACILITIES 
       J4.100 General 
       J4.200 Designated Space 
              J4.210 Routine Cleaning 
        J4.300 Environmental Monitoring 
        J4.400 Security 
 
J5.000 EQUIPMENT 
      J5.100 Selection 
      J5.200 Operation 
      J5.300 Qualification and Maintenance 
              J5.310 Requalification/Recalibration 
      J5.400 Decontamination/Sterilization 
      J5.500 Storage Unit Identification 
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K1.000 QUALITY ASSURANCE PROGRAM 
         K1.100 Basic Elements 
         K1.200 Qualification, Verification, and Validation  
                     Requirements 
                K1.210 (C, V) Validation of Shipping Containers 
                K1.220 (C, V) Validation Procedures—Packaging and  
                                       Freezing Protocols 
         K1.300 Purchasing Controls 
 
K2.000 QUALITY CONTROL PROGRAM 
        K2.100 Proficiency Testing 
        K2.200 Microbiological Tissue Cultures 
                K2.210 Pre-Sterilization/Pre-Disinfection Cultures 
                K2.220 Final/Pre-Packaging 
         K2.300 (C, V) Testing for Residues 
         K2.400 Other Quality Control Procedures 
                 K2.410 (MS) Lyophilized/Dehydrated Tissue 
                 K2.420 Annual Calibrations 
 
K3.000 MICROBIOLOGIC TESTING 
        K3.100 Transport Medium 
        K3.200 Selection of Growth Medium 
                K3.210 Quality Control of Growth Medium 
        K3.300 Microbiologic Subcultures 
K4.000 INVESTIGATIONS 
        K4.100 Errors and Accidents 
        K4.200 Complaints 
        K4.300 Adverse Outcomes 
                 K4.310 Reporting 
 
K5.000 INTERNAL AUDITS 
K6.000 ELECTRONIC SYSTEMS CONTROLS 
       K6.100 Authorized Access 
       K6.200 Error Reduction 
       K6.300 Backup Files 
       K6.400 Security 
 
L1.000 TISSUE DISPENSING SERVICES—GENERAL 
       L1.100 Responsibilities 
 
L2.000 STORAGE 
        L2.100 General 
        L2.200 Equipment 
        L2.300 Labeling 
 
L3.000 RELEASE 
        L3.100 Dispensing 
        L3.200 Release to Another Tissue Dispensing Service or  
                    Tissue Distribution Intermediary 
        L3.300 Tissue Disposal 
        L3.400 (R) Return of Tissue 
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L4.000 RECORDS 
L4.100 Tissue Receipt Records 
L4.200 Dispensing Records 
L5.000 ADVERSE OUTCOMES 
L6.000 CORRECTIONS AND REMOVALS 
 
M1.000 TISSUE DISTRIBUTION INTERMEDIARIES—
GENERAL 
 
M2.000 STORAGE 
M2.100 General 
M2.200 Equipment 
M2.300 Labeling 
M3.000 DISTRIBUTION—GENERAL 
M3.100 Tissue Distribution Restrictions 
M3.200 Transfer of Tissue to Other Tissue Banks/Dispensing 
Services 
M3.300 Requests for Donor Status and Tissue Processing 
Information 
M3.400 Distribution Records 
M3.500 Tissue Disposal 
 
M4.000 PACKAGING AND SHIPPING 
M4.100 Tissue Storage Environment 
M4.200 Validation and Packaging Expiration 
M4.300 Quality Control 
M4.400 Final Inspection 
M4.500 Transportation 
 
M5.000 RETURN OF TISSUE 
M6.000 CORRECTIONS AND REMOVALS — GENERAL 
M6.100 Correction and Removal Records 
 
M7.000 RECORDS 
M7.100 Tissue Receipt Records 
M7.200 Distribution Records 
 
M8.000 ADVERSE OUTCOMES 
 
Appendix I: REQUEST FOR VARIANCE FROM 
STANDARDS 
 
Appendix II: CRITERIA FOR PREVENTING 
TRANSMISSION of RCDADs (Relevant Communicable 
Disease Agents and Diseases) THROUGH 
TRANSPLANTATION OF HUMAN TISSUE 
 
Reference I: AATB ACCREDITATION POLICIES FOR 
TRANSPLANT TISSUE BANKS.....(not included in this 
version; see the AATB website) 
 
Reference II: AATB GUIDANCE DOCUMENTS .......(not 
included in this version; see the AATB website) 
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What can be retrieved 


Legal framework for tissue donation 
3 EC Directives 
• Directive 2004/23/EC,  
      which provides the framework 
legislation 
 
• Technical Directives  
– 2006/17/EC    
– 2006/86/EC,  
which give detailed requirements. 
 
The Advanced Therapy Medicinal 
Product (ATMP) Regulation (EC)  
No 1394/2007 
(hTEPs human tissue-engineered products) 
the legal concept of “Tissue 
Establishment” was introduced, which 
expands on the conventional concept 
of a tissue bank.  
 
Companies with an accreditation as a 
Tissue Establishment would thereby 
obtain direct access to human tissues 
and cells. 
 
These regulations have established a 
crucial legal difference between organs 
and tissues: 
 
human tissues are legally tradable 
goods in a global market. 
Tissue Establishment versus Tissue Bank 
This commercialisation of human 
tissues raises several ethical and public 
health issues.  
 
Although acknowledging the legitimacy 
of these concerns, the EC invoked the 
principle of subsidiarity—whereby the 
EU only takes action in areas, which fall 
within its exclusive competence—to 
relegate ethical and public health issues 
to the Member States 
 
EU splits responsibilities allowing diversity  
Belgian accepted Presumed consent to donation (opting –out) 
 Article 21 of the 1997 Council of Europe 
Convention of Human Rights an 
BioMedicine provides that it is not 
permissible for the human body or its 
parts as such to give rise to profits. 
 
 However, it does not prevent specific 
commercial activities, such as : 
 
 the patenting of human body material in  
• isolated 
• purified         or  
• slightly modified form 
Human dignity and profit 
Countries such as Belgium, which have an 
“opt-out” rule or presumed consent 
regime, are therefore interesting for 
brokers and corporate actors to get 
access to human tissue material for 
processing into highly profitable 
products.  
 
In this way, the values of solidarity and 
the common good that are supposed to 
underlie presumed consent are 
increasingly being eroded. 
Access to human tissues Jean-Paul Pirnay et al 
EMBO reports Vol 16 | No 5 | 2015 
Different markets, different prices to the same product: 
different access to human tissues  
Skin deviation to cosmetics  
A wide variation in prices exists, ranging from 
hundreds to thousands of dollars for the same 
product.  
 
 
In sports medicine, tendon and bone 
allografts, for instance, fetch higher prices in 
areas with a flourishing sports culture than 
tendon and bone products for general orthopaedics. 
 
cosmetics rather han medical products. 
 
 A striking example is the processing of human skin, the 
gold standard for the treatment of severe burns, into 
cosmetic products without medical indication, such as 
penis widening or lip enhancements, which fetch much 
higher prices than analogues for burn treatments.   
 
US burn centres were reportedly struggling to obtain 
skin because local tissue banks are committing all their 
donated skin to firms that market products for plastic 
and cosmetic surgery 
Presumed consent relies on citizens trust 
Presumed consent = opt-out system 
Portugal, Spain, Belgium, Austria, laws make organ 
donation the default option at the time of death  
 
people must explicitly “opt out” of organ donation. 
 
 In these so-called opt-out countries, more than 
90% of people donate their organs.  
 
Yet in countries such as U.S. and Germany, people 
must explicitly “opt in” if they want to donate their 
organs when they die.  
 
In these opt-in countries,fewer than 15% of people 
donate their organs at death 
International cooperation of non profit organizations as a solution to maintain 
Presumed Consent  trust  
Access to human tissues for research and 
product development 
From EU regulation to alarming legal developments in Belgium 
Análise económica 
• Custo Total= custos variáveis + Custos fixos  
 
• Custos variáveis ou custos directos:  
– Screening de dadores 
– Colheita de tecidos 
– Transporte 
– Análises 
– Processamento 
– Armazenamento 
– Distribuição 
– Controlo de qualidade 
  
• Custos fixos:  
– Investimentos de capital, construção de salas brancas e instalações, equipamento e aparelhos 
– salários de pessoal (administração, médico, técnicos de laboratório, administrativos, auxiliares) 
– Serviços contratados (empresas de limpeza, manutenção de instalações, manutenção de 
equipamentos)  
– Electricidade, climatização, água 
 
 
Actividades e custos atribuíveis à produção 
Screening e Colheita 
 
– Localização de dadores 
– Obtenção do consentimento/confirmação RENNDA 
– Transporte de equipas de colheita 
– História clínica e comportamental 
– Salários das equipas de procura e colheita 
– Consumíveis da colheita 
 
Comparação destes custos com o valor pago pelos 
tecidos , se forem comprados no exterior 
 
Actividades e custos atribuíveis à produção 
Estudo Analítico 
 
 
– Parcialmente diluído em dadores multiorgão 
– Testes serologia vírica 
– Testes microbiológicos 
– Testes específicos para os tecidos (Lâmpada de fenda) 
– Autópsias 
– Testes follow-up dos dadores vivos 
– Consumíveis 
– Salários do pessoal do banco de tecidos  atribuidos ao 
tempo gasto nas actividades analíticas 
 
Actividades e custos atribuíveis à produção 
Processamento 
 
– Salários atribuídos ao tempo gasto para 
transformar o tecido inicial no produto final 
(corte, invólucro, marcação) 
– Identificação do tecido e codificação 
– Esterilização 
– Refrigeração 
– Congelação controlada 
– Cultura 
– Consumíveis usados no processamento 
Actividades e custos atribuíveis à produção 
Armazenamento e distribuição 
 
• Salários atribuídos ao tempo gasto para  
– armazenamento,  
– embalamento do tecido para transporte,  
– envio do tecido  
 
•  gastos com consumíveis 
 
Controlo de Qualidade 
 
• Salários e custos com  
– Revisão médica,  
– Calibração de equipamentos 
– Manutenção Preventiva 
– Monitorização 
– Desenvolvimento de standards 
– Training e educação 
– Auditorias 
– Investigação e desenvolvimento 
 
 
 
Análise custo benefício 
• Criação e manutenção de 
– Centros de Processamento e Criopreservação 
– Centros de recolha 
 
• Versus  
 
• Colaboração internacional (ibérica por 
exemplo), com sistema idêntico de 
consentimento presumido, nos tecidos com 
excedentes nesses países 
Spain success  
(internet search) 
• Organ donations: How the Spanish transplant system works - BBC News 
• www.bbc.com/.../organ-donations-how-the-spanish-transplant-sys... 
               On Tuesday, Wales becomes the first UK nation to introduce a system where consent is assumed unless people have opted out. Spain has the highest organ ... 
 
• Margaret McCartney: When organ donation isn't a donation | The BMJ 
• www.bmj.com/content/356/bmj.j1028 - Traduzir esta página 
• de M McCartney - 2017 
• 28/02/2017 - BMJ 2017; 356 doi: https://doi.org/10.1136/bmj.j1028 (Published 28 ... “Soft opt-outboosts donation in Wales,” wrote the BMA.1 “'Dozens saved' in six ... It's worth noting 
that, in Spain—the high achiever of the organ donating ... 
 
• Opt-out proposal for organ donation presumes consent - PressReader 
• https://www.pressreader.com/uk/the.../20170511/2820118522775... - Traduzir esta página 
• Opt-out proposal for organ donation presumes consent ... The Scotsman - 2017-05-11 - Friends Of The Scotsman / Health - ... Spain has significantly higher rates of organ donation than 
Scotland, although an opt-out system has operated for ... 
 
• Increasing organ donation rates: is legislation enough? - The Lancet 
• www.thelancet.com/pdfs/.../PIIS2468-1253(17)30037-7.pdf - Traduzir esta página 
• 02/04/2017 - On Jan 1, 2017, France implemented a hard opt-out policy for organ donation. ... consent from a potential organ donor's family if the individual had ... Organización 
Nacional de Trasplantes in Spain, which has achieved the ... 
 
• Spain Organ Donation 2017 | BookInfos.org - Read eBooks ... 
• bookinfos.org/spain-organ-donation-reb.html 
• Traduzir esta página 
• Organ Donation Is When A Person Allows Healthy Transplantable Organs And Tissues To Be Some Countries With An Opt-out System Like Spain (36 Effective ... 
 
• How Spain became the world leader in organ transplants - The Local 
• https://www.thelocal.es/20170111/how-spain-became-world-lead... 
• Traduzir esta página 
• 11/01/2017 - Spain has been the world leader in organ donation for the last 25 years and in 2016 it broke its own record for ... 11 January 2017 ... Most importantly Spain operates an 
"opt-out" system in which all citizens are automatically ... 
 
• France's New Opt-Out Organ Donation System Is a Good Idea - NYMag 
• nymag.com/.../2017/01/frances-new-opt-out-organ-donation-system-is-a-good-idea.htm... 
• 03/01/2017 - Those who do wish to opt out of organ donation can fill out a form online, ... for example, Spain, which at 35.7 per 1 million people is what Leins  
 
 
• Etc…….. 
Escândalo com a  
Biomedical Tissue Services 
• N.Y. / REGION 
• Michael Mastromarino, Dentist Guilty in Organ Scheme, Dies at 49 
• By DANIEL E. SLOTNIKJULY 8, 2013 
• ….. 
• He established a network of undertakers, whom he paid up to $1,000 
per corpse, and soon took on assistants and formed a business based in 
New Jersey, Biomedical Tissue Services. He reportedly made $10,000 to 
$15,000 per body.  … 
• But Dr. Mastromarino harvested organs and tissue from bodies without 
consent from the survivors, the authorities said, and removed material 
from people with cancer, H.I.V. and other diseases. He then forged 
paperwork, including consent forms and death certificates, to make the 
cause of death and age acceptable. 
•  
 
 
07-03-2017 35 
Michael Mastromarino 
in 2006, before his 
arraignment. 
CreditSeth Wenig for 
The New York Times 
 
Onde está o histórico dos registos em Portugal? 
• BioMedical Tissue Services Scandal | Lawsuits, Lawyers | Side Effects: Infected Tissue, Infected Body Part, Rick 
Of Developing Infectious Diseases | Owner Accused, Stealing Body Parts, Forged Documents 
 
• Biomedical Tissue Services (BTS) proprietor Michael Mastromarino has been accused of stealing body parts from 
approximately 1,077 cadavers without relatives’ permission from more than 30 funeral homes. Mr. 
Mastromarino then sold the unscreened tissue for profits, and forged documents to cover his tracks. In February 
2006, the Brooklyn District Attorney in a 122-count indictment charged Mastromarino and three additional 
workers. 
• New York Police Commissioner Raymond Kelly stated in February 2006 that investigators had identified funeral 
homes in northern New Jersey, New York and one in Philadelphia had taken part in the body snatching. An ex- 
Biomedical Tissue worker told the Philadelphia Daily News in a February 2006 interview that he made 
approximately a dozen trips to the Louis Garzone Funeral Home in late 2004. During these trips, Kevin Vickers, 
the ex-Biomedical Tissue Services (BTS) worker said two to three bodies were harvested during each trip. 
• Authorities in New York have dug up more than a dozen bodies to verify that parts were illegally harvested. In 
some instances plastic hardware-store tubing would found as replacements to bones. It is believed that funeral 
home operators accepted money from the BioMedical Tissue Services (BTS) in exchange for ignoring obviously 
forged death certificates and consent forms. The body parts and tissue in question have been distributed 
throughout the country and used in thousands of operations. 
• Biomedical Tissue Services sold these illegal body parts to several large companies including 
Lifecell Corp., Regeneration Technologies, Inc., Tutogen Medical, Inc., SpinalGraft Technologies, 
LLC, Lost Mountain Tissue Bank and The Blood & Tissue Center of Central Texas. The FDA and 
most of the companies involved have not disclosed the number of patients that received the 
untested parts and tissue. 
 
• - See more at: http://www.yourlawyer.com/topics/overview/biomedical_tissue_services_scandal#sthash.XgxOyBIF.dpuf 
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Portugal  importou tecidos da BioMedical Tissue Services? 
• In New York, a Grisly Traffic in Body Parts 
• By Michael Powell and David Segal 
• Washington Post Staff Writers  
Saturday, January 28, 2006 
 
• NEW YORK -- Hundreds of very live Americans are walking around with pieces of the wrong 
dead people inside of them. 
• A macabre scandal has spread from a body-harvesting lab in New Jersey to hospitals as far 
away as Florida, Nebraska and Texas as hundreds of people discover that they have 
received tissue and bone carved from looted corpses, not least the cadaver of Alistair 
Cooke, the late and erudite host of PBS's "Masterpiece Theatre." 
• The Brooklyn district attorney and federal Food and Drug Administration inspectors are 
investigating dozens of funeral homes in New York City and Biomedical Tissue Services Ltd. 
of Fort Lee, N.J., which is run by a former dentist who, his lawyer acknowledges, abused 
intravenous pain medications while with patients. 
• The former dentist came to funeral homes, investigators say, and extracted bone, tendons 
and skin from corpses without the consent of relatives. Later, Biomedical Tissue Services 
shipped coolers full of tissue to hospitals for surgeries. A dead body can be worth tens of 
thousands of dollars when it is dissected for parts. 
• The scandal raises questions about the safety and proper supervision of a billion-dollar-
a-year industry that supplies skin and tissue for 1 million tissue transplants each year. 
But patients are most confounded by the skin-crawling fact that no one knows from whom 
the bone and tissue was harvested. 
• …… 
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Daniel George and Son Funeral 
Home is one of six Brooklyn 
funeral homes where Biomedical 
Tissue Services, headed by 
Michael Mastromarino, below, is 
alleged to have harvested body 
parts without permission. As 
many as 1,000 bodies may have 
been desecrated. (Photos By 
Andrew Theodorakis) 
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• The lack of proper tracking means that by the time problems are discovered some of the manufactured goods can’t be found. When the 
U.S. Centers for Disease Control and Prevention assists in the recall of products made from potentially tainted tissues, transplant doctors 
frequently aren’t much help. 
• 'Oftentimes there’s an awkward silence. They say: "We don’t know where it went",' said Dr. Matthew Kuehnert, the CDC’s director of 
blood and biologics. 
'We have barcodes for our [breakfast] cereals, but we don’t have barcodes for our human tissues,' Kuehnert said. 'Every patient who 
has tissue implanted should know. It’s so obvious. It should be a basic patient right. It is not. That’s ridiculous.' 
• Since 2002 the U.S. Food and Drug Administration has documented at least 1,352 infections in the U.S. that followed human tissue 
transplants, according to an ICIJ analysis of FDA data. These infections were linked to the deaths of 40 people, the data shows. 
One of the weaknesses of the tissue-monitoring system is the secrecy and complexity that comes with the cross-border exchange of body 
parts. 
• The Slovaks export cadaver parts to the Germans; the Germans export finished products to South Korea and the 
U.S.; the South Koreans to Mexico; the U.S. to more than 30 countries. 
• Distributors of manufactured products can be found in the European Union, China, Canada, Thailand, India, South 
Africa, Brazil, Australia and New Zealand. Some are subsidiaries of multinational medical corporations.  
 
• The international nature of the industry, critics claim, makes it easy to move products from place to place without much scrutiny. 
• 'If I buy something from Rwanda, then put a Belgian label on it, I can import it into the U.S. When you enter into 
the official system, everyone is so trusting,' said Dr. Martin Zizi, professor of neurophysiology at the Free University 
of Brussels. 
• Once a product is in the European Union, it can be shipped to the U.S. with few questions asked. 
 
• “They assume you’ve done the quality check," Zizi said. "We are more careful with fruit and vegetables than with body parts.”  
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• FDA inspectors also identified deficiencies with RTI's Ukrainian imports when it visited the 
company's facilities in Florida. 
 
• RTI had English translations, but not original autopsy reports, from its Ukrainian donors, 
FDA inspectors found during a 2010 audit. Those were often the only medical documents 
the company used to determine whether the donor was healthy, inspectors noted in their 
report. 
 
• Security services footage shows harvested human tissues in Ukraine labeled "Made in 
Germany". 
 
• The company told inspectors it was illegal under Ukrainian law to copy the report. But 
following the inspection it began maintaining the original Russian-language document 
along with its English translation. 
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Futuro 
Necessária análise de sustentabilidade 
dos bancos de tecido existentes 
 
Apertado controlo ético  
 
